Trial Profile
Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive (Human Epidermal Receptor) Breast Cancer: FDG-PET Response-adapted Strategy. The PHERGain Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 Feb 2024
Price :
$35
*
At a glance
- Drugs Pertuzumab (Primary) ; Trastuzumab (Primary) ; Carboplatin; Docetaxel; Fludeoxyglucose F-18; Letrozole; Tamoxifen
- Indications Early breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- Acronyms PHERGain
- Sponsors Medica Scientia Innovation Research
- 02 Feb 2024 Planned End Date changed from 1 Nov 2023 to 1 Nov 2026.
- 02 Feb 2024 Status changed from completed to active, no longer recruiting.
- 13 Dec 2023 Status changed from active, no longer recruiting to completed.